2018 Section 5 - Rhinology and Allergic Disorders

DURHAM AND PENAGOS

J ALLERGY CLIN IMMUNOL February 2016

bias

Other

24 32% L L L L L L

12 0 H U L L L L

(Continued)

Free of

selective

reporting

Incomplete outcome data

and

personnel

Blinding of

participants

Cochrane risk of bias tool

Allocation

concealment

Random

sequence

generation

Dropout rate

Total

study

duration

(Months)

pollen counts in 2nd year

resulted in

no efficacy

randomization

not reported.

Findings Observations

Low weekly

evaluation.

Method of

compared with baseline were observed in the SLIT group (both P 5 .002) and in the SCIT group ( P 5 .002 and P 5 .004,

and were unchanged (0.0; 95% CI, 2 2.65 to 1 1.52) in the

significantly reduced ( P < .02 and P < .002,

decreased cf baseline in SLIT-treated ( 2 0.36; 95% CI, 2 0.18 to 2 0.86)

and in SCIT-treated ( 2 0.75; 95% CI, 1 0.02 to 2 1.31)

(0.29; 95% CI, 2 0.82 to 1 2.57)

respectively) compared with placebo (1.35; 95% CI, 2 0.12 to

patients, both significant ( P < .002)

1 4.04). No significant differences were

2 0.22 to 1.05).

SCIT group, both

observed between SLIT and SCIT groups.

compared with placebo

(0.20; 95% CI,

Median medication scores increased

in the SLIT group

In 1st treatment season median ARC SS (scale, 0–3)

Significant decreases in symptom and medication scores

respectively). No

significant differences

were observed between

SLIT and SCIT groups.

1.83 6 1.08 1.67 6 0.91 1.42 6 1.25 1.68 6 1.28 2.74 6 1.41

6.92 6 6.00 3.24 6 3.81 3.63 6 4.50 3.10 6 3.81 7.76 6 7.44

Before After Before After Before After

—

—

SLIT SCIT Placebo

—

—

501.5 6 162.9 250.5 6 81 574.6 6 232 278.5 6 129.6

115.1 6 50.2 239.6 6 158 119.6 6 65.5

1.94 6 1.27

4.49 6 4.95

245 6 116.8

year, country Score Khinchi et al, 47

Rhinoconjunc- tivitis (peak

season week)

medications

(peak season week)

Symptom scores

Medication scores

TABLE E5. Continued

ARC rescue

Quirino et al, 48

2004,

Denmark

1996,

Italy

First author,

175